ClinicalTrials.gg
RecruitingNCT07476859HI-COR-65Updated Mar 24, 2026

Effect of Intravenous Iron on Quality of Life in Older Patients With Acute Coronary Syndrome

A Phase 4 interventional study of Ferric Carboxymaltose Injection [Ferinject] in Acute Coronary Syndromes (ACS), Iron Deficiencies and Elderly (People Aged 65 or More), sponsored by Fundación para la Investigación del Hospital Clínico de Valencia. Recruiting at 9 sites in Spain. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2026-03-24.

Sponsored by Fundación para la Investigación del Hospital Clínico de Valencia · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2026; still recruiting 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
538
Allocation
Randomized
Ages
65 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 85 studies in Acute Coronary Syndrome with a site in Spain — 13 open to participants now, 16 under way, 1 of them phase 3. Acute Coronary Syndrome · Spain.

Planned enrollment
31st of 60
538 · median 588
Started
2026
with 3 others
Phase 4
12 of 85
5 open now
Primary completion
2028-04
later than 11 of 15 live
Registered
83rd of 85
by date

Among the 85 studies in Acute Coronary Syndrome with a site in Spain, this one is the 31st largest by planned enrollment of the 60 interventional ones that give a count, is one of 4 that started in 2026, is one of 12 in phase 4, reaches primary completion later than 11 of the 15 other live ones, and was the 83rd registered.

Acute Coronary Syndrome

1,491 studies on the registry are indexed under Acute Coronary Syndrome; 272 are open to participants now.

Browse Acute Coronary Syndrome studies →

Open to participants now

13 of the 85 studies in Acute Coronary Syndrome with a site in Spain are open now. Recruiting first, the newest first:

7 more — sign in →

All 13 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 195 Acute Coronary Syndrome studies recruiting now, 144 (74%) set no upper age limit and 19 (10%) stop at 75 or younger; 15 take children under 18; 15 take healthy volunteers.

This study: 65 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 85 studies in Acute Coronary Syndrome with a site in Spain, or all of them as a file.
02

Study summary

The goal of this phase IV, open-label, randomized clinical trial is to evaluate whether intravenous iron improves quality of life in adults aged 65 years and older with iron deficiency after an acute coronary syndrome (ACS).

The main questions it aims to answer are:

  • Does intravenous iron improve quality of life at 6 and 12 months?
  • Does it reduce frailty and adverse clinical outcomes?

Researchers will compare intravenous ferric carboxymaltose with standard of care.

Participants will:

  • Be randomly assigned to receive intravenous iron or standard care
  • Attend three study visits over 12 months
  • Complete questionnaires and undergo blood tests
Read the detailed description

Acute coronary syndrome (ACS) remains one of the leading causes of morbidity and mortality in adults aged 65 years and older. Iron deficiency is a frequent condition in this population following an ACS event and has been associated with impaired functional capacity, increased frailty, worse quality of life, and poorer clinical outcomes. While intravenous iron supplementation has demonstrated clinical benefits in patients with heart failure, its role in older patients with iron deficiency after ACS has not been systematically evaluated.

This phase IV, multicenter, open-label, randomized clinical trial has been designed to assess the impact of intravenous iron administration on quality of life and clinical outcomes in older patients with iron deficiency following ACS. The study will include patients aged 65 years or older diagnosed with ACS within the previous 15 days and presenting with iron deficiency according to current European Society of Cardiology criteria.

Eligible participants will be randomized in a 1:1 ratio to receive either a single intravenous dose of ferric carboxymaltose, administered according to body weight and baseline hemoglobin levels, or standard of care without intravenous iron supplementation. Randomization will be centralized and stratified by participating center. Given the nature of the intervention, the study will be conducted in an open-label fashion.

Participants will be followed for 12 months after randomization, with study visits scheduled at baseline, 6 months, and 12 months. Throughout follow-up, comprehensive clinical assessments will be performed, including evaluation of quality of life using the EQ-5D-5L questionnaire and assessment of frailty using the FRAIL scale. Clinical events such as heart failure decompensation, recurrent myocardial infarction, stroke, and all-cause mortality will be systematically recorded.

In addition, serial blood samples will be collected to analyze iron metabolism parameters and inflammatory biomarkers. Exploratory analyses will focus on the assessment of biological aging and cardiovascular risk markers, including DNA methylation of the ELOVL2 gene, telomere length, and circulating levels of Klotho and fibroblast growth factor 23 (FGF23). These analyses aim to provide mechanistic insights into the potential effects of iron repletion on biological aging and cardiovascular risk in this vulnerable population.

The overall duration of the study is two years, including a one-year recruitment period and a one-year follow-up period. The trial is sponsored by INCLIVA - Health Research Institute and conducted across multiple centers in Spain. The results of this study are expected to provide robust clinical evidence to support optimized management of iron deficiency in older patients following ACS, with the potential to inform future clinical guidelines and improve patient-centered outcomes.

03

Conditions studied

  • Acute Coronary Syndromes (ACS)
  • Iron Deficiencies
  • Elderly (People Aged 65 or More)

Keywords

  • Acute coronary syndrome
  • Iron deficiency
  • Intravenous iron
  • Ferric carboxymaltose
  • Quality of life
  • Older adults
  • Myocardial infarction
  • Frailty
  • Cardiovascular outcomes
  • Biological aging
  • ELOVL2 methylation
  • Telomere length
  • Klotho
  • FGF23
04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥ 65 years.
  2. Hospitalization for confirmed acute coronary syndrome (ACS) within 15 days prior to enrollment.
  3. Iron deficiency diagnosed at admission or within 15 days after the index ACS event, defined as:

    • Serum ferritin \< 100 ng/mL, OR
    • Transferrin saturation (TSAT) \< 20%.
  4. Ability to provide written prior to participation.

Exclusion criteria

Exclusion Criteria:

  1. Active .
  2. End-stage or terminal illness as determined by the IDC-Pal score.
  3. Known heart failure with (LVEF) \< 40% prior to enrollment, or development of LVEF \< 40% during hospitalization or within 15 days after ACS.
  4. Chronic dialysis or advanced renal or hepatic failure.
  5. Severe anemia ( \< 10 g/dL) at the time of ACS or within 15 days after the event.
  6. Prior treatment with intravenous or oral iron within 12 months before the index ACS.
  7. Known to ferric carboxymaltose, other parenteral iron products, or any component of the formulation.
  8. Evidence of iron overload or disorders of iron metabolism.
  9. Ongoing bacteremia or active systemic infection.
  10. Participation in another interventional clinical trial involving an medicinal product.
  11. Any condition that, in the investigator's opinion, would compromise safety, protocol compliance, or study integrity.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
538 participants (estimated)

Study arms

  • Experimental
    Intervention arm

    Intravenous iron administered according to protocol and SmPC.

    Drug: Ferric Carboxymaltose Injection [Ferinject]

  • No intervention
    Control arm

    No specific intervention for iron deficiency (standard of care post-acute coronary syndrome)

Interventions

  • DrugFerric carboxymaltoseStudies of Ferric carboxymaltoseFerric carboxymaltose pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Intervention Description (Treatment Arm) Single intravenous administration of ferric carboxymaltose (Ferinject®) given at baseline within 15 days after the index acute coronary syndrome. The total iron dose is individually calculated according to body weight and hemoglobin levels, in accordance with the approved Summary of Product Characteristics (maximum 15 mg/kg, not exceeding 2,000 mg). The drug is administered in a monitored hospital setting. No additional iron doses are planned during follow-up. Intervention Description (Control Arm) Standard post-acute coronary syndrome care without specific treatment for iron deficiency. No intravenous or oral iron supplementation is administered per protocol.

06

What researchers measure

Primary outcomes

  1. Change from baseline in health-related quality of life measured using the EuroQol 5-Dimension 5-Level questionnaire (EQ-5D-5L) index score

    Change from baseline in health-related quality of life assessed using the EuroQol 5-Dimension 5-Level questionnaire (EQ-5D-5L). The EQ-5D-5L index score ranges from 0 to 1, where 0 represents the worst health state and 1 represents full health. Higher scores indicate better health-related quality of life. Scores will be evaluated at 6 and 12 months and compared with baseline between participants receiving intravenous ferric carboxymaltose and those receiving no iron treatment.

    Time frame: Baseline, Month 6 and Month 12.

Secondary outcomes

  1. Change from baseline in frailty status assessed using the Fatigue, Resistance, Ambulation, Illnesses, and Loss of Weight (FRAIL) scale

    Change from baseline in frailty status assessed using the Fatigue, Resistance, Ambulation, Illnesses, and Loss of Weight (FRAIL) scale. The FRAIL scale classifies participants as robust, pre-frail, or frail based on questionnaire responses.

    Time frame: Baseline, Month 6 and Month 12.

  2. Incidence of heart failure hospitalization

    Occurrence of hospitalizations due to decompensated heart failure during follow-up.

    Time frame: Up to 12 months

  3. Incidence of recurrent myocardial infarction

    Occurrence of non-fatal myocardial infarction during follow-up.

    Time frame: Up to 12 months

  4. Incidence of stroke

    Occurrence of ischemic or hemorrhagic stroke during follow-up.

    Time frame: Up to 12 months

  5. All-cause mortality

    Death from any cause during the 12-month follow-up period.

    Time frame: Up to 12 months

  6. Change in C-reactive protein levels (inflammatory marker)

    Change from baseline in C-reactive protein (CRP) levels. Units: mg/dl

    Time frame: Baseline and 12 months follow-up

  7. Change in high-sensitivity C-reactive protein levels (inflammatory marker)

    Change from baseline in high-sensitivity C-reactive protein (CRP) levels. Units: mg/L

    Time frame: Baseline and 12 months follow-up

Other outcomes

  1. Change from baseline in serum ferritin concentration

    Change from baseline in serum ferritin concentration measured in blood samples in a predefined subgroup of participants. Units: ng/mL

    Time frame: Baseline and 12 months

  2. Change from baseline in transferrin saturation

    Change from baseline in transferrin saturation (TSAT) measured in blood samples in a predefined subgroup of participants. Transferrin saturation will be reported as percentage (%).

    Time frame: Baseline and 12 months

  3. Change from baseline in soluble transferrin receptor concentration

    Change from baseline in soluble transferrin receptor (sTfR) concentration measured in blood samples in a predefined subgroup of participants. Concentrations will be reported in milligrams per liter (mg/L).

    Time frame: Baseline and 12 months

  4. Change from baseline in serum hepcidin concentration

    Change from baseline in serum hepcidin concentration measured in blood samples in a predefined subgroup of participants. Concentrations will be reported in nanograms per milliliter (ng/mL).

    Time frame: Baseline and 12 months

  5. Change from baseline in hypoxia-inducible factor 1 (HIF-1) levels

    Change from baseline in hypoxia-inducible factor 1 (HIF-1) levels measured in blood samples in a predefined subgroup of participants. Values will be reported in ng/ul.

    Time frame: Baseline and 12 months

  6. Change from baseline in interleukin-1 concentration

    Change from baseline in interleukin-1 (IL-1) concentration measured in blood samples in a predefined subgroup of participants. Values will be reported in nanograms per microliter (ng/µL).

    Time frame: Baseline and at 12 months follow-up

  7. Change from baseline in interleukin-6 concentration

    Change from baseline in interleukin-6 (IL-6) concentration measured in blood samples in a predefined subgroup of participants. Values will be reported in nanograms per microliter (ng/µL).

    Time frame: Baseline and at 12 months follow-up

  8. Change from baseline in interleukin-10 concentration

    Change from baseline in interleukin-10 (IL-10) concentration measured in blood samples in a predefined subgroup of participants. Values will be reported in nanograms per microliter (ng/µL).

    Time frame: Baseline and at 12 months follow-up

  9. Change from baseline in interleukin-18 concentration

    Change from baseline in interleukin-18 (IL-18) concentration measured in blood samples in a predefined subgroup of participants. Values will be reported in nanograms per microliter (ng/µL).

    Time frame: Baseline and at 12 months follow-up

  10. Change from baseline in tumor necrosis factor alpha concentration

    Change from baseline in tumor necrosis factor alpha (TNF-α) concentration measured in blood samples in a predefined subgroup of participants. Values will be reported in nanograms per microliter (ng/µL).

    Time frame: Baseline and at 12 months follow-up

  11. Change from baseline in epigenetic age acceleration measured by ELOVL2 DNA methylation

    Change from baseline in epigenetic age acceleration assessed using DNA methylation of the ELOVL2 gene in blood samples from a predefined subgroup of participants. Epigenetic age acceleration will be reported in years of biological age.

    Time frame: Baseline and at 12 months follow-up

  12. Change from baseline in telomere length

    Change from baseline in telomere length measured using the telomere-to-single copy gene (T/S) ratio in blood samples from a predefined subgroup of participants.

    Time frame: Baseline and at 12 months follow-up

  13. Association between baseline Klotho concentration and occurrence of major adverse cardiovascular events.

    Association between baseline Klotho concentration measured in blood samples and the occurrence of major adverse cardiovascular events (MACE) during follow-up in a predefined subgroup of participants. Klotho concentrations will be reported in nanograms per microliter (ng/µL).

    Time frame: Baseline and through Month 12 follow-up.

  14. Association between baseline fibroblast growth factor 23 concentration and occurrence of major adverse cardiovascular events.

    Association between baseline fibroblast growth factor 23 (FGF23) concentration measured in blood samples and the occurrence of major adverse cardiovascular events (MACE) during follow-up in a predefined subgroup of participants. Concentrations will be reported in nanograms per microliter (ng/µL).

    Time frame: Baseline and through Month 12 follow-up.

07

Study locations

5 of 9 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Apr 2028, 25 months after the start.

Of 85 non-industry phase 4 interventional studies under Acute Coronary Syndrome, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 67. This study's planned 25 months is below that.

Counting every sponsor, half of 92 studies reached it within 42 months; a quarter within 26 and three quarters within 60.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 2, 2026
First posted
Mar 17, 2026
StartActual
Mar 5, 2026
Primary completionEst.
Apr 2028
CompletionEst.
May 2028
Last update
Mar 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07476859
Lead sponsor
Fundación para la Investigación del Hospital Clínico de Valencia
Collaborators
AstraZeneca
Responsible party
Sponsor
First posted
Mar 17, 2026
Start date
Mar 5, 2026
Primary completion
Apr 2028 (estimated)
Completion
May 2028 (estimated)
Last update
Mar 24, 2026

Study contacts

Clara Bonanad Lozano, Doctor
Contact
clarabonanad@gmail.com
+34 686 10 70 71
Claudio Rivadulla Varela, Doctor
Contact
c.rivare@hotmail.com
+34 625 11 46 86

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ferric carboxymaltose

Start the discussion